Showing results (251-260 of 373) with videos related to
Sort By:
Pageof 38
Scientific Reports|December 29, 2019
High CD3 and ICOS and low TIM-3 expression predict favourable survival in resected oesophageal squamous cell carcinomaMin Hee Hong, Su-Jin Shin, Sung Kwan Shin, et al.Scientific Reports|January 11, 2014
Aberrant CDK4 amplification in refractory rhabdomyosarcoma as identified by genomic profilingSilvia Park, Jeeyun Lee, In-Gu Do, et al.Molecular Oncology|April 23, 2009
CAMK1D amplification implicated in epithelial-mesenchymal transition in basal-like breast cancerAnna Bergamaschi, Young H Kim, Kevin A Kwei, et al.Lung Cancer (Amsterdam, Netherlands)|July 20, 2019
Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinomaSehhoon Park, Joon Ho Shim, Boram Lee, et al.The Histochemical Journal|December 24, 2002
The enhanced reactivity of endogenous biotin-like molecules by antigen retrieval procedures and signal amplification with tyramineSeok Hyung Kim, Kyeong Cheon Jung, Young Kee Shin, et al.The Journal of Molecular Diagnostics : JMD|January 15, 2014
A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancerMaruja E Lira, Yoon-La Choi, Sun Min Lim, et al.Journal of Korean Medical Science|December 2, 2009
The effect of cyclooxygenase-2 expression on tumor volume response in patients treated with radiotherapy for uterine cervical cancerMin Kyu Kang, Won Park, Yoon-La Choi, et al.Brain Pathology (Zurich, Switzerland)|September 21, 2011
Mutated IDH1 is a favorable prognostic factor for type 2 gliomatosis cerebriMi Jung Kwon, Sung Tae Kim, Mi Jeong Kwon, et al.Cancer Chemotherapy and Pharmacology|July 5, 2012
Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutationSu-Hee Cho, Lee Chun Park, Jun Ho Ji, et al.Oncotarget|March 24, 2016
Phenylethanolamine N-methyltransferase downregulation is associated with malignant pheochromocytoma/paragangliomaSeung Eun Lee, Ensel Oh, Boram Lee, et al.Pageof 38